ArticlePloS one2012
Henoch schonlein purpura--a 5-year review and proposed pathway.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- National recommendations for the management of children and young people with IgA vasculitis: a best available evidence, group agreement-based approach.Archives of disease in childhood · 2024Guideline
- Activation of circulating γδ T cells in pediatric IgA vasculitis nephritis links the IL-17 A+ subset to renal risk.Scientific reports · 2026Article
- IgA Vasculitis Across the Ages: Is It Time for a Precision Medicine Approach?ACR open rheumatology · 2025Review
- The IgA Vasculitis Study: the evolution of a cross-sectional cohort into a trial-ready cohort.Rheumatology advances in practice · 2025Article
- Adverse events following Measles-Mumps-Rubella and varicella immunization: A safety profile analysis and comparison of different vaccination schedules based on the Italian Pharmacovigilance Network in the Veneto Region.Preventive medicine reports · 2024Article
- Does age at disease onset affect the clinical presentation and outcome in children with immunoglobulin A vasculitis?Archives of rheumatology · 2023Article
- Urinary markers of the alternative and lectin complement pathway are increased in IgA vasculitis nephritis.Clinical kidney journal · 2023Article
- Increased Urinary IgA in Paediatric IgA Vasculitis Nephritis.International journal of molecular sciences · 2022Article
- Urinary Protein Array Analysis to Identify Key Inflammatory Markers in Children with IgA Vasculitis Nephritis.Children (Basel, Switzerland) · 2022Article
- IgA vasculitis nephritis in children and adults: one or different entities?Pediatric nephrology (Berlin, Germany) · 2021Review
- Article
- Atypical Bacterial Pathogens and Small-Vessel Leukocytoclastic Vasculitis of the Skin in Children: Systematic Literature Review.Pathogens (Basel, Switzerland) · 2021Review
- Incidence and risk factors for recurrent Henoch-Schönlein purpura in children from a 16-year nationwide database.Pediatric rheumatology online journal · 2018Article
- A dirty cause of vancomycin-mediated Henoch-Schonlein purpura: oxygen tubing is not a foley.BMJ case reports · 2017Article
- Abnormal urinalysis on day 7 in patients with IgA vasculitis (Henoch-Schönlein purpura).Nagoya journal of medical science · 2016Article
- Henoch-Schönlein purpura with joint involvement: Analysis of 71 cases.Pediatric rheumatology online journal · 2016Article
- Urinary MCP-1/creatinine in Henoch-Schönlein purpura and its relationship with nephritis.Pediatric nephrology (Berlin, Germany) · 2014Article
- Henoch-Schönlein purpura in northern Spain: clinical spectrum of the disease in 417 patients from a single center.Medicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Henoch Schonlein Purpura (HSP) is the commonest systemic vasculitis of childhood typically presenting with a palpable purpuric rash and frequently involving the renal system. We are the first group to clinically assess, critically analyse and subsequently revise a nurse led monitoring pathway for this condition.A cohort of 102 children presenting with HSP to a secondary/tertiary level UK paediatric hospital over a five year period, were monitored using a nurse led care pathway. Using this cohort, the incidence (6.21 cases per 100,000 children per year) and natural disease course of HSP nephritis (46% initial renal inflammation; 9% subsequent renal referral; 1% renal biopsy and immunosuppression) was determined. Older patients were at higher risk of requiring a renal referral (renal referral 12.3 (8.4-13.5) years vs. normal outcome 6.0 (3.7-8.5) years; p<0.01). A normal urinalysis on day 7 had a 97% (confidence interval 90 to 99%) negative predictive value in predicting a normal renal outcome.Using this data and existing literature base, The Alder Hey Henoch Schonlein Purpura Pathway was developed, a revised pathway for the screening of poor renal outcome in HSP. This is based on a six-month monitoring period for all patients presenting with HSP, which importantly prioritises patients according to the urine findings on day 7 and thus intensively monitors those at higher risk of developing nephritis. The pathway could be easily adapted for use in different settings and resources.The introduction of a standardised pathway for the monitoring of HSP will facilitate the implementation of disease registries to further our understanding of the condition and permit future clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.